Harnessing the natural machinery of the lysosome

Scroll down

A new frontier in targeted protein degradation

We are harnessing the natural machinery of the lysosome to selectively target and degrade extracellular pathogenic proteins

Led by a team of pharma and biotech industry veterans and backed by leading European life sciences investors, we are building a differentiated, oral small molecule extracellular protein degrader platform. Our platform has broad applicability across a broad range of diseases, that are difficult to target with existing modalities

Latest news

Join us

We’re always looking for talented individuals who share our dedication to drug discovery and innovation.

Check back here regularly for open positions.

© Draupnir Bio